1. Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth.
- Author
-
Nuevo-Tapioles, Cristina, Santacatterina, Fulvio, Stamatakis, Konstantinos, Núñez de Arenas, Cristina, Gómez de Cedrón, Marta, Formentini, Laura, and Cuezva, José M.
- Subjects
TUMOR growth ,ADENOSINE triphosphatase ,NEOVASCULARIZATION ,OXIDATIVE phosphorylation ,CANCER cells ,BIBLIOTHERAPY - Abstract
Mitochondrial metabolism has emerged as a promising target against the mechanisms of tumor growth. Herein, we have screened an FDA-approved library to identify drugs that inhibit mitochondrial respiration. The β1-blocker nebivolol specifically hinders oxidative phosphorylation in cancer cells by concertedly inhibiting Complex I and ATP synthase activities. Complex I inhibition is mediated by interfering the phosphorylation of NDUFS7. Inhibition of the ATP synthase is exerted by the overexpression and binding of the ATPase Inhibitory Factor 1 (IF1) to the enzyme. Remarkably, nebivolol also arrests tumor angiogenesis by arresting endothelial cell proliferation. Altogether, targeting mitochondria and angiogenesis triggers a metabolic and oxidative stress crisis that restricts the growth of colon and breast carcinomas. Nebivolol holds great promise to be repurposed for the treatment of cancer patients. Targeting mitochondrial metabolism in cancer cells has shown promising therapeutic potential. Here, the authors screen FDA-approved compound library and show that the β1-blocker nebivolol inhibits oxidative phosphorylation and angiogenesis in cancer cells and can be re-purposed for cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF